Diligence memo · auto-generated · as of July 2, 2026
Sixfold Bioscience Inc.
Sixfold Bioscience Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Sixfold Bioscience Inc. operates in Biotech, based in WALNUT, England, United Kingdom. Delivering RNA therapies.
Sub-sector tags: biotech, pharma.
Capital & rounds (filed)filed
Sixfold Bioscience Inc. has raised $2.3M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.3M on 2021-02-23.
Most recent recorded round closed around 2021-02-23.
Valuation (modeled)modeled
Provath models Sixfold Bioscience Inc. at approximately $70M (range $1.6M–$463M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.80× the median modeled value of Seed Biotech companies in 2019–2021 (7 peers) — value vs value, same stage and era. Within the normal band (80% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 5.4 yr ago; this sector typically re-raises about every 11 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 75% of Biotech peers (233 compared).
Modeled value ranks above 85% of those peers.
Closest niche peers: Orpheus Bioscience, Inc., OneThree Biotech, Inc., Phloem Biotech, Inc., Meridian Biotech, LLC, iGenomX International Genomics Corp.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.